The University of Texas MD Anderson Cancer Center is committed to keeping our patients, our workforce members and our community safe throughout the 2019 novel coronavirus disease (COVID-19) pandemic. As part of our commitment, the institution is taking additional proactive measures to prevent the introduction or spread of COVID-19 at any of our campuses.
MD Anderson is:
Restricting entry points and screening. Entry points...
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs...
Medical experts have always known myelin, the protective coating of nerve cells, to be metabolically inert. A study led by The University...
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat rare cancers. Study findings were published in the March 18 online issue of the Journal for ImmunoTherapy of Cancer.
The open-label, Phase II study followed 127 patients who had advanced rare cancers: squamous cell carcinoma of the skin...
The University of Texas MD Anderson Cancer Center is preparing to return to normal operations on Monday morning, March 2, after operating...
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused...
Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally...
The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop...
The University of Texas MD Anderson Cancer Center today was awarded more than $20 million from the Cancer Prevention and Research Institute...
The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal...